RecruitingPhase 2NCT02523014
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Studying Meningioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Priscilla Brastianos, MD, MD, PHDMassachusetts General Hospital
- Intervention
- Vismodegib(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2028
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
- Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · GlaxoSmithKline · Genentech, Inc. · Brain Science Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02523014 on ClinicalTrials.govOther trials for Meningioma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07413796Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted SuturesMedical University of Warsaw
- RECRUITINGPHASE2NCT06955169Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRTOG Foundation, Inc.
- RECRUITINGPHASE1, PHASE2NCT07150806RYZ101 for the Treatment of Progressive or Recurrent Intracranial MeningiomaJoshua Palmer
- RECRUITINGNANCT06831461Proton Versus Photon Radiotherapy in Adults With Primary Brain TumorsTata Memorial Centre
- RECRUITINGNCT07044076Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With MeningiomasCentre Hospitalier St Anne
- RECRUITINGPHASE2NCT05940493Abemaciclib in Newly Diagnosed Meningioma PatientsNader Sanai
- RECRUITINGNCT06874426The Impact of Endoscopic Endonasal Skull Base Surgery on OlfactionUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06326190177Lu-DOTATATE for Recurrent MeningiomaEuropean Organisation for Research and Treatment of Cancer - EORTC